All In Biotech

Drug Trial Radar · NCT07223658

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Dec 22, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.

Conditions

  • Hyperlipidemia; Mixed

Interventions

  • ARO-DIMERPADrug

    Subcutaneous (SC) injection

  • PlaceboDrug

    Calculated volume to match active treatment by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 36

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site 11

    Clayton, Australia · Recruiting

  • Research Site 7

    Charlestown, New South Wales, Australia · Recruiting

  • Research Site 5

    Morayfield, Queensland, Australia · Recruiting

  • Research Site 8

    East Melbourne, Victoria, Australia · Recruiting

  • Research Site 4

    Melbourne, Victoria, Australia · Recruiting

  • Research Site 9

    Perth, Western Australia, Australia · Recruiting

  • Research Site 17

    Chicoutimi, Canada · Recruiting

  • Research Site 16

    Toronto, Canada · Recruiting

  • Research Site

    Toronto, Canada · Recruiting

  • Research Site

    Penticton, British Columbia, Canada · Recruiting

  • Research Site 13

    Tbilisi, Georgia · Recruiting

  • Research Site 14

    Tbilisi, Georgia · Recruiting

  • Research Site 15

    Tbilisi, Georgia · Recruiting

  • Research Site

    Chisinau, Moldova · Recruiting

  • Research Site 3

    Auckland, New Zealand · Recruiting

  • Research Site 2

    Auckland, New Zealand · Recruiting

  • Research Site 1

    Christchurch, New Zealand · Recruiting

  • Research Site 12

    Wellington, New Zealand · Recruiting

  • Research Site 6

    Grafton, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.